v3.26.1
Consolidated Statements of Shareholders’ Equity - USD ($)
$ in Thousands
Total
Subsidiaries
Parent Company
Common Stock
Common Stock
Parent Company
Additional Paid-in Capital
Additional Paid-in Capital
Subsidiaries
Accumulated Other Comprehensive (Loss) Income
(Accumulated Deficit) / Retained Earnings
(Accumulated Deficit) / Retained Earnings
Parent Company
Noncontrolling Interests
Noncontrolling Interests
Subsidiaries
Beginning balance (in shares) at Mar. 31, 2023       760,143,393                
Beginning balance at Mar. 31, 2023 $ 1,607,587     $ 0   $ 4,933,137   $ (2,617) $ (3,772,754)   $ 449,821  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of the Company’s common shares, net of issuance costs (in shares)       19,600,685                
Issuance of the Company’s common shares, net of issuance costs 199,822         199,822            
Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares)       18,926,077                
Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments 10,857         10,857            
Issuance of the Company's common shares related to settlement of warrants (in shares)       7,554,549                
Issuance of the Company’s common shares related to settlement of warrants 83,264         83,264            
Issuance of the Company's common shares related to settlement of transaction consideration (in shares)       313,023                
Issuance of the Company's common shares under employee stock purchase plan (in shares)       140,227                
Issuance of the Company’s common shares under employee stock purchase plan 951         951            
Issuance of subsidiary common shares, net of issuance costs 238,733         129,763         108,970  
Exercise and vesting of subsidiary share awards 5,742         3,192         2,550  
Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries 0         (106,531)         106,531  
Deconsolidation of subsidiaries (35,148)                   (35,148)  
Dividend declared by subsidiary (6,000)                   (6,000)  
Disposition of Telavant (87,500)                   (87,500)  
Share-based compensation 199,951         142,037         57,914  
Foreign currency translation adjustment (936)             (1,466)     530  
Net (loss) income 4,231,206               4,348,926   (117,720)  
Amounts reclassified from accumulated other comprehensive (loss) income 0                      
Contribution from minority interest holder to subsidiary 0                      
Unrealized losses on available-for-sale securities 0                      
Ending balance (in shares) at Mar. 31, 2024       806,677,954                
Ending balance at Mar. 31, 2024 6,448,529     $ 0   5,396,492   (4,083) 576,172   479,948  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares)       17,503,515                
Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments 7,354         7,354            
Issuance of the Company's common shares under employee stock purchase plan (in shares)       118,640                
Issuance of the Company’s common shares under employee stock purchase plan 1,028         1,028            
Issuance of subsidiary common shares, net of issuance costs 124,429         77,267         47,162  
Exercise and vesting of subsidiary share awards 5,027         2,852         2,175  
Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries 0         (142,100)         142,100  
Deconsolidation of subsidiaries (3,706)                   (3,706)  
Share-based compensation 289,123         224,315         64,808  
Foreign currency translation adjustment (5,210)             (5,148)     (62)  
Net (loss) income (356,734)               (171,981)   (184,753)  
Sale of interests in subsidiary (48,079)                   (48,079)  
Repurchase of the Company’s common shares (in shares)       (128,361,786)                
Repurchase of the Company’s common shares (1,293,232)         (1,005,101)     (288,131)      
Change in fair value of debt due to change in subsidiary credit risk (1,200)             (1,200)        
Amounts reclassified from accumulated other comprehensive (loss) income 19,869             19,869        
Contribution from minority interest holder to subsidiary 0                      
Unrealized losses on available-for-sale securities $ 0                      
Ending balance (in shares) at Mar. 31, 2025 695,938,323     695,938,323                
Ending balance at Mar. 31, 2025 $ 5,187,198     $ 0   4,562,107   9,438 116,060   499,593  
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments (in shares)       48,518,151                
Issuance of the Company’s common shares in connection with equity incentive plans, net of forfeitures, and tax withholding payments 136,891         136,891            
Issuance of the Company's common shares under employee stock purchase plan (in shares)       121,724                
Issuance of the Company’s common shares under employee stock purchase plan 1,155         1,155            
Exercise and vesting of subsidiary share awards 54,455         26,998         27,457  
Issuance of subsidiary common shares to the Company and cash contributions to majority-owned subsidiaries 0         (162,659)         162,659  
Share-based compensation 346,165         295,065         51,100  
Foreign currency translation adjustment (3,027)             (1,525)     (1,502)  
Net (loss) income (397,907)               (299,771)   (98,136)  
Repurchase of the Company’s common shares (in shares)         (24,225,812)              
Repurchase of the Company’s common shares   $ (1,400) $ (318,103)       $ (1,318)     $ (318,103)   $ (82)
Amounts reclassified from accumulated other comprehensive (loss) income (976)             (976)        
Vesting of Earn-Out Shares 57,685         57,685            
Issuance of subsidiary common shares, net of issuance costs 193,605         108,902         84,703  
Contribution from minority interest holder to subsidiary 39,250                   39,250  
Unrealized losses on available-for-sale securities $ (2,579)             (2,579)        
Ending balance (in shares) at Mar. 31, 2026 720,352,386     720,352,386                
Ending balance at Mar. 31, 2026 $ 5,292,412     $ 0   $ 5,024,826   $ 4,358 $ (501,814)   $ 765,042